AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Novel Antigen for Immunization in Cancer

Detailed Technology Description

Experiments have also been conducted using transgenic mice engineered to mimic the human immune system. The prototype telomerase vaccine induced a CTL response in these mice with no apparent negative side effects, demonstrating the potential of this vaccine in an animal model. Since telomerase is essential in the normal process of cell division, autoimmune reactions are a concern for this type of vaccine. However, in addition to the lack of side effects observed in the mouse model, tests of the vaccine on normal human stem cells, which have higher levels of telomerase than other normal cells, showed no adverse effects.

Supplementary Information

Patent Number: US7388071B2
Application Number: US2001788110A
Inventor: Zanetti, Maurizio
Priority Date: 15 Feb 2000
Priority Number: US7388071B2
Application Date: 15 Feb 2001
Publication Date: 17 Jun 2008
IPC Current: A61K003800 | A01N003718 | A61K003514 | A61K003900 | A61P003500 | C07K000706 | C07K000708
US Class: 530300 | 530328 | 514002 | 514015 | 514021
Assignee Applicant: The Regents of the University of California
Title: Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
Usefulness: Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
Summary: The vaccine is useful for treating cancer or tumors, for targeting cytotoxic T lymphocytes to tumor cells, and for inducing or augmenting a cancer patient's immune response against tumor (claimed).
Novelty: Vaccine for initiating and enhancing a cytotoxic T lymphocyte response, for treating cancers or tumors or for inducing immune response against tumors, comprises a telomerase reverse transcriptase peptide

Industry

Disease Diagnostic/Treatment

Sub Group

Cancer/Tumor

Application No.

7388071

Others

State Of Development

This technology is available for licensing. See U.S. patent number 7,338,071 issued on 06/17/08 “Composition and Methods for Inducing and Enhancing a Telomerase Reverse Transcriptase—Reactive Cytotoxic T Lymphocyte Response.” Also see the continuing application, U.S. Publication Number US2009/0074741.

Tech ID/UC Case

19221/2000-051-0

Related Cases

2000-051-0

Country/Region

USA

For more information, please click Here